Stay updated on Lebrikizumab Long-term Safety Efficacy AD Clinical Trial
Sign up to get notified when there's something new on the Lebrikizumab Long-term Safety Efficacy AD Clinical Trial page.
Latest updates to the Lebrikizumab Long-term Safety Efficacy AD Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe Locations section was expanded to include a global list of study sites, expanding geographic coverage; several location groupings were removed, altering the available sites.SummaryDifference2%
- Check46 days agoChange DetectedRevision label updated from v3.3.1 to v3.3.2; no impact on the study details or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%
- Check53 days agoChange DetectedPublication notes now state that PubMed feeds are automatically filled and add Revision: v3.3.1; the previous PubMed-based description has been removed (Revision: v3.2.0).SummaryDifference0.4%
- Check60 days agoChange DetectedAdded a new Lebrikizumab long-term data publication to the Publications section and removed the NIH funding-status notice.SummaryDifference0.1%
- Check67 days agoChange DetectedThe page adds Open-Label Extension Addendum arms for Lebrikizumab Q4W and Q8W (up to 32 weeks) and new primary/secondary outcomes (AE discontinuation, IGA 0/1 at Week 100, EASI-75 at Week 100), plus updated study protocol documents.SummaryDifference0.4%
- Check74 days agoChange DetectedThere are no significant changes detected on the page; the study details and layout appear unchanged from the previous view.SummaryDifference0.1%
Stay in the know with updates to Lebrikizumab Long-term Safety Efficacy AD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lebrikizumab Long-term Safety Efficacy AD Clinical Trial page.